Prolaris is a genomic test risk stratification tool developed to aid healthcare professionals in predicting prostate cancer aggressiveness in conjunction with clinical parameters such as Gleason score and PSA. The test provides unique additional information that can be combined with standard clinical factors to make the most accurate prediction of a patient’s prostate cancer aggressiveness Prolaris has been extensively validated across multiple patient cohorts in both pre and post-treatment scenarios.
Prostate Cancer